Parkinson disease: an update

The Neurologist
Steven J Frucht

Abstract

Over the past decade, the treatment of Parkinson disease (PD) has undergone tremendous changes. New drugs have been introduced to manage the cardinal motor symptoms of PD, and other agents have been borrowed to treat the nonmotor manifestations of the illness. For neurologists faced with the task of treating PD patients, the available array of medications may be confusing and intimidating. In this review, I summarize the newest approved medications for the treatment of PD, including the new dopamine agonists and catechol-O-methyl-transferase inhibitors. I also describe agents that are used to treat common problems in PD patients, including hallucinations, orthostasis, nausea, erectile dysfunction, depression, and memory loss. Guidelines for handling common scenarios in PD patients will be illustrated by 10 case histories. Finally, the most promising PD drugs that are currently in development will be reviewed. Neurologists have a vast armamentarium to treat both motor and nonmotor manifestations of PD. Understanding this array allows the astute clinician to improve the lives of their patients with PD.

References

Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
May 1, 1984·The American Journal of Psychiatry·J E Thornton, S M Stahl
Jul 1, 1993·The American Journal of Medicine·J JankovicF M Fouad-Tarazi
Mar 1, 1994·Epilepsia·E SassoD Mancia
Feb 1, 1993·Archives of Neurology·A J HughesA J Lees
Feb 6, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A D KorczynF Stocchi
Sep 30, 1998·Lancet·F AssalL Rubbici-Brandt
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezM Rosenfeld
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·T A ZesiewiczR A Hauser
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S J FruchtS Fahn
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·R A HauserT A Zesiewicz
Jun 1, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·S HolroydG F Wooten
Aug 25, 2001·Nihon rinsho. Japanese journal of clinical medicine·K Miyoshi
Nov 3, 2001·Brain Research. Brain Research Reviews·A D ZurnP Aebischer
Mar 26, 2002·Brain : a Journal of Neurology·Andrew J HughesAndrew J Lees
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Ruth DjaldettiEldad Melamed
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group

❮ Previous
Next ❯

Citations

Mar 22, 2006·Biological cybernetics·H R RabieM I Glavinović
Mar 23, 2007·European Journal of Pharmacology·Dariusz PogockiElzbieta Wałajtys-Rode
Mar 18, 2006·Acta Neurologica Scandinavica·C VossiusJ P Larsen
Nov 20, 2016·Bioanalysis·Marcia Cristina Teixeira Dos SantosAndre Nogueira da Costa
Sep 19, 2018·Brain Sciences·Rashad HussainMuhammad Shahab
Jul 12, 2017·Journal of Molecular Neuroscience : MN·Fatemeh Nouri Emamzadeh
Oct 22, 2019·International Review of Psychiatry·Julie M JoyceChantel T Debert
Aug 5, 2017·Frontiers in Molecular Neuroscience·Ernesto Miranda-MoralesOscar Arias-Carrión

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Internal Medicine
Andrew Siderowf, Matthew Stern
Biological Psychiatry
Amir H Rezvani, Edward D Levin
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
M R PicciottoV Zachariou
© 2022 Meta ULC. All rights reserved